Date: 2015-03-17
Type of information: Opening of new premises
Compound:
Company: Quantum Genomics (France) Inserm (France)
Therapeutic area: Cardiovascular diseases
Type agreement: creation of a joint laboratory
Action mechanism:
Disease: hypertension
Details: * On March 17, 2015, Quantum Genomics announced the creation of a joint laboratory with the INSERM laboratory led by Catherine Llorens-Cortes at the Collège de France. Within this joint laboratory, referred to as CARDIOBAPAI, Quantum Genomics and the “Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions” team, led by Dr Catherine Llorens-Cortes, leading Research Director for the INSERM at the Collège de France and winner of the Prix Galien France 2014 for pharmaceutical research, will pool their expertise to carry out cross-sectional research on the innovative therapeutic platform developed by Quantum Genomics, i.e. Brain Aminopeptidase A Inhibitors (BAPAIs).
This collaboration will enable Quantum Genomics to enhance its knowledge on BAPAIs, while the company starts a phase IIa clinical trial for QGC001, its most advanced drug candidate in the fight against high blood pressure.
The joint CARDIOBAPAI laboratory has been approved by the French National Agency for Research (ANR), which will provide a subsidy of 300K€ for three years (2015 to 2017). The CARDIOBAPAI laboratory work, which combines molecular modelling and biology, biochemistry, medicinal chemistry and in vivo pharmacology, will more specifically target the programme of combination with other antihypertensive agents, new indications and a better knowledge of the mechanism of action.
The laboratory will enable some of the regular staff at the Collège de France, post-PhD researchers and PhD students from the team led by Dr Catherine Llorens-Cortes, to work together with the Quantum Genomics’ research team. The company plans to enhance its team by recruiting a researcher specialised in pharmacology and another specialised in medicinal chemistry. Placed under the leadership of Catherine Llorens-Cortes, the laboratory will therefore bring together molecular modellers, chemists, molecular biologists and pharmacologists under one roof. the laboratory will work closely with the Clinical Investigation Centre of the Hôpital
Européen Georges Pompidou, managed by Professor Michel Azizi, main investigator in the phase IIa clinical trial on the drug candidate QGC001 initiated by Quantum Genomics. A steering committee, made up of Catherine Llorens-Cortes, Fabrice Balavoine and Lionel Ségard, CEO of Quantum Genomics, will meet on a quarterly basis to monitor the science and budget of
the programme.
Financial terms:
Latest news:
